Decoy Therapeutics Inc. is a pre-clinical stage biotechnology company. It is advancing peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform, which uses peptide coiled-coil chemistry and physics together with computational and machine learning tools to design alpha-helical peptides. The platform also applies machine learning, artificial intelligence, and synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting unmet medical needs, with a portfolio focused on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and changed its name to Decoy Therapeutics Inc. in January 2026. It is based in Houston, Texas.